ALKS - Alkermes Plc - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ALKS is currently covered by 13 analysts with an average price target of $34.34. This is a potential upside of $6.91 (25.19%) from yesterday's end of day stock price of $27.43.

Alkermes Plc's activity chart (see below) currently has 310 price targets and 236 ratings on display. The stock rating distribution of ALKS is 57.14% BUY, 38.1% HOLD and 4.76% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 73.29% with an average time for these price targets to be met of 228.27 days.

Highest price target for ALKS is $46, Lowest price target is $26, average price target is $37.45.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 21-Jul-2025. First documented stock forecast 17-Oct-2013.

Split History since 2000:

5/15/00 2 for 1

Currently out of the existing stock ratings of ALKS, 24 are a BUY (57.14%), 16 are a HOLD (38.1%), 2 are a SELL (4.76%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$46

$19.4 (72.93%)

$46

22 days ago
(21-Jul-2025)

19/24 (79.17%)

$19.34 (72.54%)

295

Buy

$43

$16.4 (61.65%)

$32

28 days ago
(15-Jul-2025)

13/19 (68.42%)

$14.15 (49.05%)

631

Hold

$42

$15.4 (57.89%)

$38

1 months 26 days ago
(17-Jun-2025)

2/4 (50%)

$12.23 (41.08%)

86

Buy

$40

$13.4 (50.38%)

$35

8 months 30 days ago
(13-Nov-2024)

4/6 (66.67%)

$10.76 (36.80%)

699

Buy

$36

$9.4 (35.34%)

$25

9 months 7 days ago
(05-Nov-2024)

20/27 (74.07%)

$7.63 (26.89%)

141

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ALKS (Alkermes Plc) average time for price targets to be met?

On average it took 228.27 days on average for the stock forecasts to be realized with a an average price target met ratio 73.29

Which analyst has the current highest performing score on ALKS (Alkermes Plc) with a proven track record?

MICHAEL SCHMIDT

Which analyst has the most public recommendations on ALKS (Alkermes Plc)?

Michael Schmidt works at GUGGENHEIM and has 5 price targets and 3 ratings on ALKS

Which analyst is the currently most bullish on ALKS (Alkermes Plc)?

Jonathan Eckard with highest potential upside - $39.4

Which analyst is the currently most reserved on ALKS (Alkermes Plc)?

Terence Flynn with lowest potential downside - -$10.6

Alkermes Plc in the News

Alkermes Second Quarter 2025 Earnings: Beats Expectations

Alkermes (NASDAQ:ALKS) Second Quarter 2025 Results Key Financial Results Revenue: US$390.7m (down 2.1% from 2Q 2024). Net income: US$87.1m (down 8.0% from 2Q 2024). Profit margin: 22% (down from 24% in 2Q 2024). EPS: US$0.53 (down from US$0.56 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from...

ALKS- Positive Narcolepsy Drug Trial Puts this Biotech Name in Focus

Alkermes Plc (ALKS) recently announced positive topline data from its Phase II Vibrance-1 trial of alixorexton (formerly ALKS 2680) in patients with narcolepsy type 1 (NT1). The Vibrance-1 trial is a global, randomized, double-blind, placebo-controlled multiple dose trial, notes John McCamant, editor of Medical Technology Stock Letter. To get more articles and chart analysis from...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?